Funding opportunities for investigators

Multinational Clinical Trial Funding Opportunities

ECRIN can provide support to investigators for the preparation of calls for multinational clinical trial funding. If projects are funded and meet ECRIN eligibility criteria, we can subsequently offer various trial management services.

For more information on how ECRIN can support you in the preparation of these calls, see Trial Preparation and contact your local European Correspondent.

There is a dedicated page for the list of calls for funding for COVID19. It is curated by ECRIN and updated on a weekly basis. Find the relevant information here.

The calls listed below may be relevant for your applications for clinical trials / clinical research in various fields.

Note: additional information on calls on diverse topics other than clinical trials (e.g. training) may be found in the News section (select "Calls" to filter). 

Past Calls

Date added
13-04-2021
Deadline
06-05-2021
Deadline 2
06-05-2021
Description

The European Commission has launched a call in the COVID-19 HERA Incubator part of the Horizon Europe Framework Programme. The information below can be found here.

 

ExpectedOutcome:

This topic aims at supporting activities that are enabling or contributing to the development of large scale, COVID-19 cohorts and networks worldwide, including beyond Europe’s borders, forging links with European initiatives as a global response to the pandemic. To that end, proposals under this topic should aim at delivering results that are directed, tailored towards and contributing to all of the following expected outcomes:

  • In the short-term, contribution to a better understanding of the global circulation of the current and emerging SARS-CoV-2 variants of concern and their characteristics, delivering recommendations on the best strategies to control viral spread, as well as on optimized clinical management and treatment of COVID-19 patients.

  • In the short-term, contribution to the evaluation of the impact of the variants of concern on the different vaccines and vaccination strategies and information on best vaccine and treatment options.

  • In the short/medium/long-term, monitoring the emergence of new variants of concern, elucidating the impact of different variants on transmissibility and severity of COVID-19 disease, including long-term post-infection sequelae (long COVID).

  • In the long term, establishment of regional and internationally linked strategic cohorts that can be pivoted rapidly to research on emerging infectious diseases.

  • In the long-term, contribution to regional and international pandemic preparedness networks to rapidly address pandemics in the future on a global scale.

 Scope:

Proposals submitted under this expression of interest are expected to build on existing large-scale, multi-centre, regional or international cohorts worldwide and/or establish new ones linked to those. These cohorts should aim to rapidly advance the knowledge on SARS-CoV-2 and its emerging variants of concern, with the aim of developing evidence-based strategic and robust recommendations for the effective control and prevention of COVID-19 infection. The regional or international cohort(s) should allow to rapidly and consistently provide estimations on the occurrence and spread of emerging variants of concern in different parts of the world. They should contribute to a better understanding of their transmissibility, virulence and pathogenicity.

Risk and protective factors to infection, and clinical manifestation including long-term post-infection sequelae (long COVID) should be investigated for different variants and different (risk) groups (e.g. children, elderly) to potentially identify biomarkers for vulnerable populations and inform treatment options.

The cohort(s) should also contribute to elucidating the effectiveness of the various first-generation vaccines and the risk of reinfection in previously infected individuals in the different cohort populations, including risk groups, to inform on optimal vaccine strategies. The effectiveness of second-generation or adjusted vaccines should be considered as soon as they become available.

Clinical studies, carried out within the cohort(s), might also help to inform best treatment options and vaccine strategies.

The cohort(s) should cover different regions of the world to capture the various variants and vaccine and treatment strategies.

To allow for harmonised, high-quality data collection, standardisation of clinical protocols facilitated data sharing and coordination across existing cohorts, a strong collaboration with the EU-funded projects ORCHESTRA and RECODID, as well as the EU COVID-19 data portal[1] is expected. Applicants should describe their plans for such collaborations in the proposal[2].

Applicant consortia are expected to collaborate with other relevant initiatives already existing or under development at national, regional, and international level, in order to maximise synergy and complementarity and avoid duplication of the research efforts. Coordination across cohorts and established clinical trial networks on COVID-19 treatment and vaccines is encouraged to improve research outcomes.

Strong collaboration with regional public health and regulatory authorities is strongly encouraged.

Proposals should include a plan on maintaining the established cohort(s) to strengthen regional or international research preparedness for a future epidemic or pandemic.

If more than one proposal is successful, proposals should collaborate and this should be foreseen in the proposal.

Gender-related issues are an important crosscutting priority of this Expression of Interest. All data should be sex- and gender-disaggregated, and attention should be paid to critical social factors intersecting with sex/gender, such as age, social origin, ethnicity/migration, and disability.

This action seeks to address the challenges linked to the COVID-19 variants. As such, the granting authority has activated the public emergency provisions included in the General Annexes, meaning that beneficiaries must comply with the public emergency related provisions listed in the General Annexes of the Work Programme 2021 (part G - Legal and financial set-up of the grant agreements) and in the Model Grant Agreement concerning the project implementation under Intellectual Property Rights (IPR), background and results, access rights and rights of use (article 16 and Annex 5) for the duration of the pandemic; and under Communication, dissemination, open science and visibility (article 17 and Annex 5) during the entire duration of the action and for four years after the end of the action.

It is expected that quality-controlled data are shared in accordance with the FAIR[3] principles. The use of harmonised protocols in collaboration with other actors is recommended for this purpose.

For the selection of proposals for funding, the Commission will take the geographical distribution of activities into account.

The Commission considers that proposals requesting a contribution from the EU of between EUR 7 and 10 million would allow these specific challenges to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Please note that expenditures can be covered from the date of submission of the proposal, but at the applicant’s own risk.

Proposals can be concise and should focus on the essential information to facilitate an appropriate evaluation.

[1]https://www.covid19dataportal.org

[2]Applicants should not contact these projects before they submit the proposal as this would lead to work overload for the applicants as well as the mentioned projects. Applicants should indicate in their proposal which networks/projects would be relevant for their proposed work. If their application is successful, the Commission will facilitate the connection between the coordinator/project and the relevant network/project(s) at the time the grant preparation will start.

[3]FAIR data are data, which meet principles of findability, accessibility, interoperability, and reusability. https://www.openaire.eu/how-to-make-your-data-fair

Date added
12-04-2021
Deadline
06-05-2021
Deadline 2
06-05-2021
Description

The European Commission has launched a call in the COVID-19 HERA Incubator part of the Horizon Europe Framework Programme. The information below can be found here

ExpectedOutcome:

This topic aims at supporting activities that enable the conduct of vaccine & therapeutic trials to boost prevention and further inform public health policy and clinical management. To that end, proposals under this topic should aim for delivering results that are directed, tailored towards and contributing to two of the three expected outcomes listed below:

  • Enrichment of the current portfolio of SARS-CoV-2 /COVID-19 prophylactics and therapeutics with clinical testing of promising candidates.
  • Further development of new, or adjustment of existing, vaccine candidates to be effective against the current SARS-CoV-2 variants and potentially protect against new emerging ones.
  • Development of new effective therapies against SARS-CoV-2 for the clinical management of COVID-19 disease, including for the prevention of disease progression to severe illness and hospitalisation.

 Scope:

Proposals submitted under this expression of interest should aim to further develop promising therapeutic or prophylactic candidates against SARS-CoV-2/COVID-19. The vaccine/treatment candidates should have completed preclinical development, including animal studies, and be ready to enter clinical evaluation in Phase I or II studies. Applicants should have addressed the current viral variants of concern in their pre-clinical work, and/or anticipated the emergence of new variants. Proposals should include a summary of results obtained in the concluded studies (pre-clinical and/or Phase I). Proposals are also expected to include assurances on sufficient and timely access to GMP production of the compound(s) to be trialled (the costs of which can be included in the proposal). In addition, options to upscale production for subsequent development beyond the activities for which funding is requested, should be indicated as appropriate.

The proposed interventions should address, and be assessed for, different age population groups, including children and pregnant women, and target specific groups of interest such as immunocompromised, patients with co-morbidities or other groups with higher risk to develop severe disease, and patients suffering from long-term health consequences of COVID-19.

The therapeutic interventions to be developed should aim at treating mild to moderate illness (e.g. antivirals, antibodies, immunomodulators). Therapeutic interventions targeting severe to critical illness resulting from the infection are excluded.

Thermostability, innovative delivery systems, affordability and the flexibility of the platforms to speedily adjust the candidates to emerging variants, should be also considered when possible.

Applicants are expected to engage early on with the European Medicines Agency (EMA) to ensure adequacy of the proposals from a regulatory point of view.

Collaboration with one of the large European trial networks VACCELERATE, RECOVER or EU-RESPONSE projects is expected and applicants are encouraged to describe their plans for such collaboration in the proposal[1].

Proposals should envisage an appropriate level of collaboration with existing European research infrastructures, and should link to the COVID-19 data portal[2] for the timely sharing of relevant data.

Gender-related issues are an important crosscutting priority of this Expression of Interest. All data should be sex- and gender-disaggregated, and attention should be paid to critical social factors intersecting with sex/gender, such as age, social origin, ethnicity/migration, and disability.

This action seeks to address the challenges linked to the COVID-19 variants. As such, the granting authority has activated the public emergency provisions included in the General Annexes, meaning that beneficiaries must comply with the public emergency related provisions listed in the General Annexes of the Work Programme 2021 (part G - Legal and financial set-up of the grant agreements) and in the Model Grant Agreement concerning the project implementation under Intellectual Property Rights (IPR), background and results, access rights and rights of use (article 16 and Annex 5) for the duration of the pandemic; and under Communication, dissemination, open science and visibility (article 17 and Annex 5) during the entire duration of the action and for four years after the end of the action.

It is expected that quality-controlled data are shared in accordance with the FAIR[3] principles. The use of harmonised protocols in collaboration with other actors is recommended for this purpose.

The Commission expects to select at least one proposal on a vaccine and one on a therapeutic candidate for funding.

The Commission considers that proposals requesting a contribution from the EU of between EUR 3 and 10 million would allow these specific challenges to be addressed appropriately, with phase I trials expected to be at the lower end of this spectrum. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Please note that expenditures can be covered from the date of submission of the proposal, but at the applicant’s own risk.

Proposals can be concise and should focus on the essential information to facilitate an appropriate evaluation.

[1]Applicants should not contact these projects before they submit the proposal as this would lead to work overload for the applicants as well as the mentioned projects. Applicants should indicate in their proposal which networks/projects would be relevant for their proposed work. If their application is successful, the Commission will facilitate the connection between the coordinator/project and the relevant network/project(s) at the time the grant preparation will start

[2]https://www.covid19dataportal.org

[3]FAIR data are data, which meet principles of findability, accessibility, interoperability, and reusability. https://www.openaire.eu/how-to-make-your-data-fair

 

Date added
14-01-2021
Deadline
16-03-2021
Deadline 2
12-07-2021
Description

JPIAMR is launching an international call for projects under the umbrella of the JPIAMR and within the framework of the ERA-NET JPIAMR-ACTION. The call, with financial support from the European Commission, includes 30 funding organisations from 21 JPIAMR member countries, see complete list below. The total estimated call budget is 24.9 million Euro.

Date added
07-01-2021
Deadline
09-03-2021
Deadline 2
30-06-2021
Description

The call is for proposals in transnational research projects on neurodevelopmental disorders. The aim is to coordinate research efforts and funding programmes across Europe and beyond to promote disease-related biomedical research on neurodevelopmental disorders

Date added
14-12-2020
Deadline
04-03-2021
Deadline 2
17-06-2021
Description

The Preliminary Announcement of the European Joint Programme on Rare Diseases (EJP RD) Joint Transnational Call (JTC) 2021 is online. The topic is:  “Multidisciplinary research projects on personalised medicine - development of clinical support tools for personalised medicine implementation”. There will be a two-stage submission procedure for joint applications: pre-proposals and full proposals. 

Key dates: The call is planned to be launched on December 14th 2020 with a submission deadline for preproposals on March 4th 2021. It is expected that consortia invited for the full-proposal stage, will need to submit their proposal on June 17 th , 2021

 

 

Date added
23-10-2020
Deadline
14-01-2021
Description

KCE and ZonMw jointly launch a second call for the research community to submit clinical trial proposals. The available budget is 9 million euro.

In clinical practice, many treatments have not been thoroughly evaluated, making it unclear whether a patient benefits from a particular treatment, or which treatment is actually preferable. Evaluation of clinical practice is relevant to health care stakeholders in Belgium and the Netherlands and by working together, clinical evaluation trials can be carried out more quickly and efficiently. 

The aim of the BeNeFIT (Belgium-Netherlands Funding of International Trials) program is to provide funding for non-commercial practice-oriented research that is immediately relevant to patients, caregivers and policymakers in Belgium and the Netherlands and is conducted in collaboration by research institutions from both countries.

The deadline for submission of a research outline is 14 January 2021, 14.00h. 

Date added
30-01-2020
Deadline
12-02-2020
Description

The European Commission has issued a call to advance knowledge for the clinical and public health response to the coronavirus epidemic. The information below can be found here as well. 

Specific Challenge:
On 31 December 2019, the local authorities of Wuhan, Hubei province, China, reported a cluster of pneumonia cases of unknown origin. On 9 January 2020, the China Centre for Disease Control reported a novel Coronavirus (2019-nCoV) to be the causative agent.

As of 30 January 2020, 7824 laboratory-confirmed cases of 2019-nCoV have been reported including 170 deaths[1]. The disease has already spread to 19 countries outside China, with new cases continuing to emerge daily.

Recalling the SARS-CoV epidemic in 2003 with over 8000 cases reported (10% case fatality), it is crucial to rapidly gain a better understanding of the newly identified virus, especially in relation to potential clinical and public health measures that can be put to immediate use to improve patients’ health and/or contain the spread of 2019-nCoV.

Scope:
Proposals submitted under this expression of interest are expected to advance the knowledge on 2019-nCoV and its impact on infected persons, with the aim of contributing to an efficient patient management and/or public health preparedness and response. Proposals must be timely, with rapid activation, to enable early and valuable outcomes to be established. For increased impact, proposals may wish to build on promising avenues from previous or ongoing research.

Considering that this is a newly identified virus, the scope of this expression of interest remains broad and may include topics such as:

Development of therapeutics, including monoclonal antibodies. As relevant, evidence of regulatory and ethics approvals for the investigational products included in the study(ies) must be presented.
Development of point of care diagnostics, ensuring rapid evaluation of candidates based on existing technologies, to allow for fast case detection and surveillance.
Clinical and epidemiological studies, to provide data on epidemiological characteristics such as viral genotype and pathogenicity; clinical information on host susceptibility and host immune responses; risk factors for severe disease; routes of transmission and their relative importance; identification of the animal reservoir; etc.
Social sciences research, to provide urgently needed answers to social dynamics of the outbreak and the related public health response.
Proposals covering investigation of therapeutic and/or vaccines should consider engaging with the European Medical Agency (EMA) to ensure adequacy of the proposals from a regulatory point of view, i.e. via the innovation task force[2], scientific advice or consultation in the context of the health threats interactions[3] [4].

Where relevant, proposals should consider the close collaboration with leading European supercomputing centres to use high-end computing, data and simulation resources in order to accelerate the processes of diagnosis and vaccine research and development. In this respect, the Supercomputing facilities in Barcelona (BSC) and Bologna (Cineca) are open to collaborate with any interested proposer or successful proposal. Other leading European supercomputer centres, such as the organisations hosting the PRACE Tier-0 supercomputers, may also be interested in such collaborations.

Applicants should be aware that proposals funded under this expression of interest will be required to make available their research data, in accordance with the relevant option of Article 29.3 of the H2020 model grant agreement. The use of harmonised protocols in collaboration with other actors is recommended for this purpose.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts. Please note that expenditures can be covered from the date of submission of the proposal, but at the applicant’s own risk. Proposals can be concise and should focus on the essential information to facilitate an appropriate evaluation.

Expected Impact:
To contribute to the diagnosis and clinical management of patients infected by 2019-nCoV.
To contribute to the public health preparedness and response in the context of the ongoing epidemic of 2019-nCoV.
Cross-cutting Priorities:
Socio-economic science and humanities
Gender
Open Innovation

[1]https://www.ecdc.europa.eu/en/novel-coronavirus-china

[2]https://www.ema.europa.eu/en/human-regulatory/research-development/innovation-medicines#ema's-innovation-task-force-(itf)-section

[3]https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-advice-protocol-assistance/requesting-scientific-advice-protocol-assistance-ema

[4]https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats

Date added
13-12-2019
Deadline
01-04-2020
Description

The Preliminary Announcement of the European Joint Programme on Rare Diseases (EJP RD) Joint Transnational Call (JTC) 2020 is online. The topic is: PRE-CLINICAL RESEARCH TO DEVELOP EFFECTIVE THERAPIES FOR RARE DISEASES. There will be a two-stage submission procedure for joint applications: pre-proposals and full proposals. The call is scheduled to open on December 13, 2019.

 

Date added
26-06-2019
Deadline
26-09-2019
Deadline 2
26-03-2020
Description

Call ID: H2020-JTI-IMI2-2019-18-two-stage
Action Type: RIA – Research and Innovation Actions
Topics

For full details of the topics, including the budget breakdown and the General Conditions for the Call for proposals, click on the links above (which take you directly to the relevant page of the Participant Portal) or read the IMI2 - Call 18 Text.

Indicative budget

  • From EFPIA companies and IMI2 Associated Partners: EUR 85 871 760
  • From the IMI2 JU: EUR 74 866 000

Key dates and deadlines

  • Draft topic texts published: 10 April 2019
  • Publication date: 26 June 2019
  • Stage 1 submission start date: 26 June 2019
  • Stage 1 submission deadline: 26 September 2019 (17:00:00 Brussels time)
  • Stage 2 submission deadline: 26 March 2020 (17:00:00 Brussels time)

How to apply

All documents relating to the Call can be found via the Funding and Tenders Portal and the IMI2 Call documents page, in particular the IMI Manual for evaluation, submission and grant award - version 1.7.

Detailed guidance on how to submit a proposal, including a detailed user manual and frequently asked questions, can be found under the Submit a Proposal section of the Participant Portal Horizon 2020 Online Manual.